A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

Inclusion Criteria:

• Signed informed consent
• Active subfoveal or juxtafoveal choroidal neovascularization secondary to AMD
• Best Corrected Visual Acuity (BCVA) between 70-25 letters (ETDRS) at Screening
• Intraretinal or subretinal fluid
• Central Subfield Thickness > 300 µm

Exclusion Criteria:

• Pregnant or breastfeeding females or those with a positive pregnancy test.
• Females of childbearing potential who will not use a medically acceptable contraceptive method
• Current, previous chronic or recurrent condition according to the investigator's judgement.
• Concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications
• Concurrent disease in the study eye
• Previous treatment with systemic anti-Vascular Endothelial Growing Factor (Anti-VEGF) drugs or pro-VEGF treatments
• Concurrent disease in the study eye, other than AMD